Team Leader in Breast Cancer Target Validation
The Institute of Cancer Research
Role Managed by:
t: 020 7340 6283
Primary Practice Group: Higher Education and Research
Salary & Benefits: Competitive
Closing Date: 31/01/2022
Formal Interview Date: April 2022
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes with an outstanding track record of achievement dating back more than 100 years. Our mission is to make the discoveries that defeat cancer, which we seek to achieve through world-leading research and internationally excellent learning and teaching.
Today, The Institute of Cancer Research (ICR) is rated as the UK’s leading higher education institution for the quality and impact of our research. We are world leaders in the identification of cancer-related genes, discovery of new targeted cancer drugs and development of new forms of high-precision radiotherapy. Our unique partnership with The Royal Marsden NHS Foundation Trust and integrated 'bench to bedside and back again’ approach ensure our research advances rapidly reach patients and place us among the top four centres in the world for cancer research and treatment.
The Division of Cancer Therapeutics has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. The Division houses the Cancer Therapeutics Unit (CTU) as one of the largest academic cancer drug discovery groups in the world. With our collaborators, CTU has discovered 20 preclinical development candidates since 2005, 11 of which have been progressed to clinical evaluation. Our drug abiraterone (Zytiga) has been approved in the US, Canada, and Europe for late-stage prostate cancer.
The Breast Cancer Now Toby Robins Research Centre has been at the forefront of many of the key breakthroughs in breast cancer research. Core funded by Breast Cancer Now (BCN), the Centre functions as a truly translational research centre. Examples of pioneering discoveries from the Centre include: (a) the discovery of PARP inhibitor synthetic lethality that has revolutionised the treatment of BRCA1/2 mutant cancers, (b) step-change improvements in biomarkers and treatments for oestrogen receptor positive breast cancers, (c) innovations that allow treatment to be adapted according to evidence of response or resistance, and (d) advances in the dissection of breast cancer genetics and biology which are now informing the identity of the next generation of breast cancer treatments. With colleagues in the Division of Cancer Therapeutics, the BCN Centre are discovering new drugs for use in the disease.
The ICR is now seeking an established research leader in breast cancer drug discovery to work in a role integrating the BCN Centre with the CTU. This is a senior faculty position (Reader or Professorial Level), and as such, we seek an individual who will work closely and collaborate with other faculty to identify candidate drug targets from their own and others’ work, carry out in-depth target validation on such candidates and then lead and prosecute multidisciplinary breast cancer drug discovery programmes that emerge from this work. The successful candidate will thus work closely with Directors of both BCN Centre and CTU to build an internationally recognised strength in breast cancer drug target validation in both Centres, as well as contributing to the overall scientific life of the ICR, by providing mentorship to more junior colleagues and acting as an academic leader.
The appointment will be based on track-record, the ability and willingness to engage in team science and the ability to inform the prevention and treatment of breast cancer.
The ICR has engaged Perrett Laver to support the Appointment Panel for this role. For informal enquiries about the role please contact Michael Coleman on +44 (0)20 7340 6283 or by sending an email to Michael.Coleman@perrettlaver.com.
The closing date for applications is at 9am (GMT) on Monday 31st January 2022. Final stage interviews will take place in April 2022.
For a conversation in confidence, please contact Michael Coleman on +44 (0)20 7340 6283 or by sending an email to Michael.Coleman@perrettlaver.com
Should you require access to these documents in alternative formats, please contact Lina Franzen on firstname.lastname@example.org
If you have comments that would support us to improve access to documentation, or our application processes more generally, please do not hesitate to contact us via email@example.com
Data Protection and Privacy
Protecting your personal data is of the utmost importance to Perrett Laver and we take this responsibility very seriously. Any information obtained by our trading divisions is held and processed in accordance with the relevant data protection legislation. The data you provide us with is securely stored on our computerised database and transferred to our clients for the purposes of presenting you as a candidate and/or considering your suitability for a role you have registered interest in.
As defined under the General Data Protection Regulation (GDPR) Perrett Laver is a Data Controller and a Data Processor, and our legal basis for processing your personal data is ‘Legitimate Interests’. You have the right to object to us processing your data in this way. For more information about this, your rights, and our approach to Data Protection and Privacy, please visit our website: www.perrettlaver.com/information/privacy